Complications and mortality in patients with schizophrenia and diabetes: population-based cohort study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26294369.
- Also identified by DOI 10.1192/bjp.bp.113.143925.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The long-term outcome of patients with both diabetes and schizophrenia remains unclear. To explore whether having schizophrenia increases the risk of advanced complications and mortality in people with diabetes. This is a population-based matched cohort study using Taiwan's National Health Insurance Research Database. A total of 11 247 participants with diabetes and schizophrenia and 11 247 participants with diabetes but not schizophrenia were enrolled. We used Cox proportional hazard models to determine the effect of schizophrenia on macrovascular and microvascular complications, and all-cause mortality. The adjusted hazard ratios were 1.49 (95% CI 1.32-1.68) for macrovascular complications, 1.05 (95% CI 0.91-1.21) for microvascular complications and 3.68 (95% CI 3.21-4.22) for all-cause mortality in patients with diabetes and schizophrenia compared with those patients with diabetes but not schizophrenia. Patients with both diabetes and schizophrenia had an increased risk of macrovascular complications and all-cause mortality but did not have statistically significant elevated risk of microvascular complications.
Medical subject headings
- Diabetes Mellitus, Type 2
- Schizophrenia